Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 4

Sponsor Class

OTHER 26INDUSTRY 22NIH 4FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gynecologic 1

Conditions

Melanoma 2Carcinoma, Basal Cell 2Neoplasm Metastasis 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Imiquimod × Dermatologic × Clear all
NCT00453050 2015-05-06

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

National Cancer Institute (NCI)

Phase 1 Completed
11 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00066872 2013-09-17

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

National Cancer Institute (NCI)

Phase 3 Completed
500 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00079300 2013-04-26

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
Dermatologic

Carcinoma, Basal Cell

NCT00273910 2012-10-19

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
104 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡